2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Renal Dysfunction in Patients with Left Ventricular Assist Device

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Late-stage heart failure and renal dysfunction are often seen in conjunction. Cardiorenal syndrome (CRS) describes the complex interaction between the two disease states. Early literature described the pathophysiology of CRS as related only to reduced cardiac output and decreased renal perfusion. Recent literature suggests a more multifaceted mechanism. Left ventricular assist devices (LVAD), used as bridge-to-transplant and destination therapy in patients with heart failure, impact not only cardiac function but also renal function, especially in those patients with preoperative renal dysfunction. The mechanism by which LVAD implantation affects renal function is complex and understated in early literature. In this review, we discuss the pathogenesis of CRS, the impact of preoperative renal dysfunction in patients undergoing LVAD implantation, and the effect of LVAD implantation on postoperative renal function.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Heart Disease and Stroke Statistics—2020 Update

          Circulation
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association

            Cardiorenal syndrome encompasses a spectrum of disorders involving both the heart and kidneys in which acute or chronic dysfunction in 1 organ may induce acute or chronic dysfunction in the other organ. It represents the confluence of heart-kidney interactions across several interfaces. These include the hemodynamic cross-talk between the failing heart and the response of the kidneys and vice versa, as well as alterations in neurohormonal markers and inflammatory molecular signatures characteristic of its clinical phenotypes. The mission of this scientific statement is to describe the epidemiology and pathogenesis of cardiorenal syndrome in the context of the continuously evolving nature of its clinicopathological description over the past decade. It also describes diagnostic and therapeutic strategies applicable to cardiorenal syndrome, summarizes cardiac-kidney interactions in special populations such as patients with diabetes mellitus and kidney transplant recipients, and emphasizes the role of palliative care in patients with cardiorenal syndrome. Finally, it outlines the need for a cardiorenal education track that will guide future cardiorenal trials and integrate the clinical and research needs of this important field in the future.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Seventh INTERMACS annual report: 15,000 patients and counting.

              The seventh annual report of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) summarizes the first 9 years of patient enrollment. The Registry includes >15,000 patients from 158 participating hospitals. Trends in device strategy, patient profile at implant and survival are presented. Risk factors for mortality with continuous-flow pumps are updated, and the major causes/modes of death are presented. The adverse event burden is compared between eras, and health-related quality of life is reviewed. A detailed analysis of outcomes after mechanical circulatory support for ambulatory heart failure is presented. Recent summary data from PediMACS and MedaMACS is included. With the current continuous-flow devices, survival at 1 and 2 years is 80% and 70%, respectively.
                Bookmark

                Author and article information

                Contributors
                Journal
                Methodist Debakey Cardiovasc J
                Methodist Debakey Cardiovasc J
                1947-6108
                Methodist DeBakey Cardiovascular Journal
                Houston Methodist DeBakey Heart & Vascular Center
                1947-6094
                1947-6108
                06 September 2022
                2022
                : 18
                : 4
                : 19-26
                Affiliations
                [1 ]Methodist DeBakey Heart & Vascular Center, Houston Methodist, Houston, Texas, US
                [2 ]Texas A&M College of Medicine, Bryan, Texas, US
                Author notes
                CORRESPONDING AUTHOR: Ashrith Guha, MD, MPH Methodist DeBakey Heart & Vascular Center, Houston Methodist, Houston, Texas, US gashrith@ 123456houstonmethodist.org
                Author information
                https://orcid.org/0000-0002-0026-5127
                https://orcid.org/0000-0002-7246-9508
                Article
                10.14797/mdcvj.1146
                9461688
                36132586
                57fd463e-26e5-4c49-8d53-672bda58e8ff
                Copyright: © 2022 The Author(s)

                This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.

                History
                : 08 June 2022
                : 14 July 2022
                Categories
                Review

                lvad,left ventricular assist device,renal dysfunction

                Comments

                Comment on this article